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Secondary obstructive cholangiopathy is characterized by intra- or extrahepatic bile tract obstruction. Liver inﬂammation
and structural alterations develop due to progressive bile stagnation. Most frequent etiologies are biliary atresia in children,
and hepatolithiasis, postcholecystectomy bile duct injury, and biliary primary cirrhosis in adults, which causes chronic biliary
cholangitis. Bile ectasia predisposes to multiple pathogens: viral infections in biliary atresia; Gram-positive and/or Gram-negative
bacteria cholangitis found in hepatolithiasis and postcholecystectomy bile duct injury. Transmembrane toll-like receptors (TLRs)
are activated by virus, bacteria, fungi, and parasite stimuli. Even though TLR-2 and TLR-4 are the most studied receptors related
to liver infectious diseases, other TLRs play an important role in response to microorganism damage. Acquired immune response
is not vertically transmitted and reﬂects the infectious diseases history of individuals; in contrast, innate immunity is based on
antigenrecognitionbyspeciﬁcreceptorsdesignatedaspatternrecognitionreceptorsandistransmittedverticallythroughthegerm
cells. Understanding the mechanisms for bile duct inﬂammation is essential for the future development of therapeutic alternatives
in order to avoid immune-mediated destruction on secondary obstructive cholangiopathy. The role of TLRs in biliary atresia,
hepatolithiasis, bile duct injury, and primary biliary cirrhosis is described in this paper.
1.InnateImmunity
Innate immunity acts, responds, modulates, and provides
defense against viral and bacterial infections through trans-
membrane cell receptors encoded in the germ line, among
them are the Toll-like receptors (TLRs). As part of the innate
immune response, there are several endogenous antibiotics
againstbacterial(lactoferrins,lysozymes,anddefensins),and
viral infections (interferon-1β and MxA-protein); cytokines
and chemokines also participate signiﬁcantly in acquired
immunity. Biliary epithelial cells secrete immunoglobulin
A in relation to pathogen-associated molecular patterns
(PAMPs). When biliary epithelium gets in touch with a
pathogen,itisthenactivatedbyPAMPsandinducesdiﬀerent
mechanisms to prevent or limit tissue damage by means
of Toll-like receptor-3 (TLR-3), which in turn stimulates
transcriptional nuclear factor-κB( N F - κB) after production
of antiviral interferon-1β (IFN-1β)[ 1]. The bowel has
to react to pathogens while keeping tolerance to normal
commensalﬂora.TLRsplayanimportantroleinthisdelicate
balancebecausetheyinduceactivationofinnateandadaptive
immune response, that is why a low expression of TLRs
is found on epithelial gut cells to maintain tolerance to
microorganisms [2].
2.HepatobiliaryTractInnateImmunity
Many symptomatic infectious diseases of the biliary tract
are characterized by neutrophil migration across the epithe-
lium and accumulation within the lumen. Transepithelial
migration of neutrophils represents an important factor in
mucous epithelium defense of inﬂammatory diseases. When
inﬂammatory reaction starts on biliary epithelium, neu-
trophils traverse vascularendothelium to lamina propria and
reach epithelium. Transepithelial migration of neutrophils
can be initiated by stimulation of interleukin-8 (IL-8) as
a consequence to host-pathogen interaction and regulated2 Gastroenterology Research and Practice
by early events in response to transepithelial migration
of CD11b/CD18-β2 integrin. Pathogen microorganisms by
themselves can release bacterial peptides such as N-formate,
potent neutrophil chemoattractant in transepithelial migra-
tion [3].
Biliary innate immunity is actively involved in inﬂam-
mation by secreting cytokines (IL-1β, tumor necrosis factor-
alpha (TNF-α), and IL-6), chemotactic cytokines (monocyte
chemotactic protein (MCP-1), inhibitory factor macrophage
migration (MIF)), proinﬂammatory proteins, reactive oxy-
gen species, and adhesion molecules and expression of
receptors that recognize microorganisms, such as TLRs in
biliary epithelium cells, which provides protection against
bacterial and viral infections. On the other hand, biliary
epithelium is constantly exposed to PAMPs that do not
trigger inﬂammatory responses, denominated as immune
tolerance, which maintains homeostasis between the body
and commensal bacterial ﬂora, thus avoiding excessive
damage to the epithelium [4]. It has been shown certain
cross-tolerance of biliary epithelial cells, monocytes, and
intestinal epithelial cells [5] to lipopolysaccharides (LPSs)—
TLR ligands-4—after their exposure for 24h, observed by
overexpression of IRAK-M which interferes in the associa-
tion between IL-1 receptor-associated kinase (IRAK-1) and
myeloid diﬀerentiation factor 88 (MyD88) [6].
3.Toll-Like Receptors
ThirteenhomologousrecipientstoTLRshavebeendescribed
in mammals of which 10 have been described in humans
[7]. TLRs are part of pattern recognition receptors (PRRs),
well-conserved multigene family in humans which plays an
importantroleininnateandadaptiveimmunitybyrecogniz-
ing unique structural components of bacteria, fungi, viruses,
and damage-associated molecular patterns (DAMPs). TLRs
are transmembrane receptors expressed in most immune
cells including polymorphonuclear and epithelial cells.
They have an extracellular 24-to-29-aminoacid domain
with leucine-rich regions (LRRs), one or two cysteine-
rich regions, and a 200-aminoacid intracellular domain,
similar to that described in the family of interleukin-1
receptors (IL-1R), called Toll/IL-1R (TIR), which performs
signal transduction [8]. TLRs can also act as intracellular
receptors related to individual characteristics of pathogen
components, such as nucleic acids, proteins, lipids, and
carbohydrates. Binding substrates couple to TLRs lead-
ing to signaling and activation of innate and adaptive
inﬂammatory response, which represents a bridge between
both systems since the activation of innate immune sys-
tem induces phagocytosis, opsonization, and production
of inﬂammatory mediators, blocking the spread of the
pathogen. After recognizing their ligands, TLRs expressed
on antigen-presenting cells (APCs) are activated and induce
molecules involved in presenting antigenic peptides on the
surface. In the major histocompatibility complex (MHC),
peptides are recognized by antigen-speciﬁc T cells, thus
joining the innate and adaptive immune response [9]. PAMP
can be compromised by TLRs, as they are basic character-
istics of the microorganisms that cannot be modiﬁed by
geneticmutationsinashorttime[10].Descriptionofhuman
TLRs is provided next, and Table 1 contains their main
characteristics.
3.1. Toll-Like Receptor-1, -2, and -6. TLR-1 is a member of
the innate immune system family receptors [11]. It recog-
nizes PAMP speciﬁcally from Gram-positive bacteria, also
known as CD281. TLR-1 inhibits phenol-soluble modulin
response mediated by TLR-2 secreted by Staphylococcus
epidermidis and participates in the recognition of soluble
factors released by Neisseria meningitidis.
Speciﬁc activation by homo- or heterodimerization of
TLR-2 on hepatitis C core proteins along with TLR-1 and
TLR-6 and reduction of cytokines production by blocking
these receptors have been reported, suggesting that hepatitis
C proteins activate innate immune reckoning [12].
TLR-6 was identiﬁed on knockout mice as a coreceptor
necessary for recognition of diacylated lipopeptides, while
TLR-1 forms heterodimers with TLR-2 and recognizes
triacylated lipopeptides structures. TLR-1 gene is expressed
in all cells at high levels and recognizes peptidoglycan in
accordance with TLR-2 as heterodimer, which is found on
the surface of macrophages and neutrophils [13].
TLR-1, TLR-6, and TLR-10 can form heterodimers with
TLR-2 by increasing the speciﬁcity of their ligands [14, 15].
It has been shown that TLR-2 plays an important role
in lipid transport through lipoproteins uptake. It appears
that TLR-2 deﬁciency protects from nonalcoholic fatty liver
disease and probably modiﬁes the signaling pathway of TLR-
4[ 16]. TLR-2 activation requires the presence of leucine-rich
c o f a c t o r ss u c ha sC D 1 4 .T h e s er e c e p t o r sa r el o c a t e do nc e l l
membrane and they recognize peptidoglycan, lipoteichoic
acid and lipoproteins of Gram-positive bacteria, spirochetal
LPS, zymosan from fungi, Treponema maltophilum gly-
copeptides, glucoinositol phospholipid from Trypanosoma
cruzi and modulin [14]. TLR-6 recognizes Mycoplasma
and Borrelia burgdorferi lipoproteins along with TLR-2 and
also recognizes diﬀerences between acylated lipopeptides of
pathogen microorganisms [17, 18].
3.2. Toll-Like Receptor-3. TLR-3 reacts to dsRNA from virus-
es and apoptotic and/or necrotic cells. Dying cells can ac-
tivate TLR-3 by an activating ligand. TLR-3 in the liver may
mediate innate activity and inﬂammation and induces type
I IFN production during viral infections. Finally, TLR-3 is
overexpressed in the endosome of dendritic cells [19].
3.3. Toll-Like Receptor-4. TLR-4 was the ﬁrst one to be dis-
covered and is considered the most important because it
is the ﬁrst to respond to LPS ligand, also best known
for his sensitivity to detect LPS in Gram-negative bacteria
membrane. TLR-4 constitutes the largest component of
the LPS recognition receptor complex (coreceptors CD14
and MD-2) [20, 21], and its signaling can be activated
by some cellular components of endogenous ligands which
are released or increased during tissue injury and matrix
degradation (DAMPs) [22]. This receptor is involved in LPSGastroenterology Research and Practice 3
Table 1: Toll-like receptor(TRLs) characteristics. Some TLRs recognize proteins, lipids, and nucleic acids from RNA or DNA of pathogens
by inducing innate immune response. Stimulation of TLRs starts with the activation of intracellular signals resulting in secretion of
proinﬂammatory cytokines such as type 1 IFN, TNF-α, and IL-6 depending on the causal agent.
Location Function Stimulates Inhibits or interferes
Toll-like receptor
(TLR)
(i) Transmembrane
receptors expressed in most
immune cells including
polymorphonuclear and
epithelial cells
(ii) Intracellular receptor
function
(i) Induction of
phagocytosis, opsonization,
and production of
inﬂammatory mediators,
(i) Innate and adaptive
inﬂammatory response
(i) The spread of the
pathogen
TLR-1
(i) Expressed on the surface
of all cells at high levels
(ii) Recognizes
peptidoglycan
(iii) Found on
macrophages and
neutrophils
(i) Recognition of PAMP
from Gram-positive
bacteria
(ii) Reduction of cytokines
production
(i) Heterodimers increasing
the speciﬁcity of their
ligands
(i) Phenol-soluble modulin
TLR-2
(i) Expressed on cell
membranes surface
(ii) Found on macrophages
and neutrophils
(i) Lipid transport through
lipoproteins uptake
(ii) Formation of
heterodimers
(iii) Recognition of
triacylated lipopeptides,
structures of
peptidoglycan, lipoteichoic
acid and lipoproteins of
Gram-positive bacteria,
spirochetal LPS, zymosan
from fungi, Treponema
maltophilum glycopeptides,
glucoinositol phospholipid
from Trypanosoma cruzi
and modulin
(i) Requires the presence of
leucine-rich cofactors such
as CD14
(i) Deﬁciency protects from
nonalcoholic fatty liver
disease
TLR-3
(i) Intracellular expression
on endosomes of myeloid
DCs
(i) Reaction to dsRNA from
viruses and apoptotic
and/or necrotic cells
(i) Type I IFN production
during viral infections and
NF-κB
(i) Antagonist
TLR-4 (i) Expressed on all cell
surface
(i) First to respond to LPS
ligand
(ii) Detection of LPS in
Gram-negative bacteria
membrane
(i) IRAK-M
(ii) Cellular components
(iii) Endogenous ligands
which are released or
increased during tissue
injury and matrix
degradation
(iv) Synthesis of
inﬂammatory cytokines
and type I IFN
(i) IRAK-1, MyD88, and
NF-κB
TLR-5 (i) Expressed on all cell
surface
(i) Recognition of bacterial
ﬂagellin protein of
Salmonella typhimurium
(ii) Induction of
inﬂammatory responses via
a MyD88-dependent or
independent pathway
(i) Initiation or
ampliﬁcation of Th2-type
(ii) Innate immunity
(iii) Apoptotic signaling
pathways and
proinﬂammatory
(i) I-κBd e g r a d a t i o n
(ii) NF-κBa c t i v a t i o nf o r
soared tissue4 Gastroenterology Research and Practice
Table 1: Continued.
Location Function Stimulates Inhibits or interferes
TLR-6
(i) Expressed in myeloid
and monocyte-derived
dendritic cells (DCs)
(ii) Not expressed on
plasmacytoid DCs (pDCs)
(i) Recognition of
Mycoplasma and Borrelia
Burgdorferi
(ii) Diﬀerences between
acylated lipopeptides of
pathogen microorganisms
(iii) Formation of
heterodimers with TLR-1,
TLR-2, and TLR-10
(i) Speciﬁcity of ligands
from TLR-1, TLR-2, and
TLR-10
(i) Antagonist
TLR-7
(i) Expressed on endosome
of dendritic cells, human
plasmacytoid cells, myeloid
cells, and
monocyte-derived cells
(i) Recognition of
imidazoquinolines
(i) Type I IFN production
during viral infections
(ii) Agonists of TLR-7
(i) Antagonists
TLR-8 (i) Intracellular expression
(i) Detection of
pathogen-derived nucleic
acids (ssRNA)
(i) Type I IFN
MyD88-dependent (i) Antagonists
TLR-9 (i) Intracellular expression
(i) Recognition of bacterial
DNA with unmethylated
motifs
(ii) Activation in viral
infections
(iii) Recognition of DNA
from viral infections
(i) Type I IFN (i) Antagonists
TLR-10
(i) TLR2/1, TLR2/10
complexes recruit the
proximal adaptor MyD88
(i) Receptor complex
requires TLR-2 for innate
immune recognition
(ii) Related to TLR1 and
TLR6
(iii) Mediate immune
responses to a variety of
microbe and fungi
(i) Proximal adaptor
MyD88 to the activated
receptor complex
(ii) Without a deﬁned
agonist alone or in
cooperation with TLR2
(i) TLR-induced signaling,
including NF-κB-, IL-8, or
IFN-beta-driven reporters
endotoxin response that occurs on the cell surface of Gram-
negative bacteria by activating signaling pathways, resulting
in synthesis of inﬂammatory cytokines and type I IFN. Its
activationrequiresthepresenceofcosignalingreceptorsMD-
2, although some TLR-4 can generate the signal in absence of
CD14 [23].
3.4. Toll-Like Receptor-5. TLR-5 recognizes the bacterial
component ﬂagellin protein of Salmonella typhimurium.
Flagellin is a potent activator of systemic inﬂammation in
humans, and its serum levels are positively correlated with
clinicalseverityinpresenceofbacteremicshockbyplayingan
important role in the immunopathogenesis of inﬂammatory
bowel disease. Flagellinis also capable of activating apoptotic
signaling pathways and proinﬂammation and can lead to
activation of innate immunity [24].
3.5. Toll-Like Receptor-7. TLR-7 is involved in recognition
of imidazoquinolines. These receptors induce type I IFN
production during viral infections and are expressed on
endosome of dendritic cells, human plasmacytoid cells,
myeloid cells, and monocyte-derived cells; thereby, its ex-
pression on diﬀerent body systems depends on the number
of dendritic cells held by each organ.
3.6. Toll-Like Receptor-8. TLR-8 is activated in viral infec-
tions producing type I IFN. It belongs to a family of endo-
somic recognition pattern receptors capable of producing
type I IFN MyD88-dependent and detect pathogen-derived
nucleicacids.HumanmonocytesconstitutivelyexpressTLR-
8[ 25].
3.7. Toll-Like Receptor-9. TLR-9 recognizes bacterial DNA
with unmethylated motifs. Apoptotic bodies containing
microkernels are a source of DNA. The unmethylated motifs
of cytosine-phosphate-guanosine- (CpG-) DNA are recog-
nized by TLR-9. TLR-9-deﬁcient mice manifest less liver
injury in response to poisoning by carbon tetrachloride, bile
duct ligation, acetaminophen and fatty liver hepatitis model.
TLR-9 activates diﬀerent signaling cascades resulting in
generation of myoﬁbroblasts by hepatic stellate cells (HSCs),
collagen type 1, and overexpression of the proﬁbrogenicGastroenterology Research and Practice 5
cytokine TGF-β because its eﬀects can be blocked by TLR-
9 antagonists, suggesting activation of the innate immune
response within the HSC. The TLR-9 responds to viral
infections by producing type I IFN [26].
3.8. Toll-Like Receptor-10. T L R - 1 0i sa no r p h a nm e m b e r s
of human TLRs. It shares a common locus on chromosome
4p14 [27]. In experimental models TLR-10 is predominantly
expressed in immune cells-rich tissues such as small bowel,
stomach, thymus, peripheral blood lymphocytes, lymph
nodes, and tonsils [28]. In co-immunoprecipitation studies
an association with TLR-1 and TLR-2 through extracellular
domains has been demonstrated, and also an important
role by inducing production of IFN type I on plasmacytoid
dendritic cells. TLR-10 in humans recognizes conserved
motifs of bacteria and viruses, resulting in inﬂammation
mediated by TLRs activating transcription factor NF-κBa n d
IFN regulatory factor [29].
4. TLRs in LiverDamage andInﬂammation
Diﬀerent cholangiopathies result from biliary tract dysfunc-
tion, and they can be divided into autoimmune, genetic,
infectious, drug-induced, or ischemic, and on the other
hand by complete biliary obstruction with intra- and
extrahepatic bile stasis; therefore the pathogenesis of some
cholangiopathies remains unclear, which results in limited
treatments.
TLRs are expressed on the liver, an organ that receives
blood from the portal circulation of lower extremities
and bowel with frequent exposure to PAMPs of invading
microorganisms and antigenic components of the diet;
therefore, healthy liver can develop immunological tolerance
[30]. PAMPs are detected in normal and pathological
bile indicating that biliary epithelial cells are exposed to
bacterial components under physiological and pathological
conditions [31]. Hepatocytes express mRNA for all TLRs
[32, 33] but only TLR-2 and TLR-4 show functional activity
ofendotoxemia clearanceincirculation[34].Bothparenchy-
mal and nonparenchymal liver cells express TLR-4 and are
actively involved in the response to diﬀerent types of liver
injury. Liver injury, regardless of etiology, including viral
hepatitis, alcoholic and nonalcoholic disease, autoimmune
liver diseases induced by drugs, and other diseases that
prevent free passage of bile into duodenum with complete
intra- or extrahepatic bile duct obstruction, is associated
with increased hepatic exposure to bacterial products. When
liver sinusoidal endothelial cells are exposed to low levels of
LPS, it can result in loss of expression and desensitizing of
TLR-4 [35].
5.HepaticImmune Response
Liver immune response is complex due to competition of
many cell populations, including lymphocytes binding with
naturalkiller(NK)andCD8+Tcellswhichmaybeunusually
abundant.Dendriticcells(DCs)andactivatedhepaticstellate
cells (HSCs) show TLR-4 signals which participate in hepatic
inﬂammation and ﬁbrogenesis. These cells can respond to
TLRs signals and act as antigen-presenting cells for T cells.
TLRs have been found in the liver when infected with
viral hepatitis B or C, and also in animal models of bile
duct injury induced by ligation, partial hepatectomy, drug
toxicity (acetaminophen), and ischemia-reperfusion. TLR-4
is speciﬁc for LPS by transferring the signal inside the cell
and promoting translocation of NF-κB into the nucleus with
transcriptional activation of chemokines-encoding genes
and pro- and anti-inﬂammatory cytokines [36].
6. TLRs inLiverFibrosis
Any immune or inﬂammatory liver disease activates Kupﬀer
cells; these can trigger production of inﬂammatory cytokines
(IL-6, IL-8, and TNF-α) with subsequent activation of
HSCs, promoting ﬁbrogenesis (excessive deposit extracellu-
lar matrix proteins) and TLRs participation, which results
in cirrhosis and liver failure. The activation of HSCs is
controlled by many cytokines and growth factors, including
TGF-β which is considered the main inductor on trans-
formation of HSCs, while growth factor platelet-derived
(PDGF)playsacriticalroleinstimulatingtheproliferationof
HSCs. Recent studies suggest that TLR-4 participates in the
production of hepatic ﬁbrosis by activation of HSCs by TGF-
β [37]. Yokoyama et al. showed that TLR-2 and TLR-4 are
capable of mediating innate immune system on intrahepatic
biliary epithelial cells. Furthermore, increased expression of
TLR-4 on biliary epithelium in primary biliary cirrhosis [38]
after bile duct ligation on experimental studies [37] suggests
TLRs role in the development of chronic inﬂammation and
liver ﬁbrosis (Figure 1).
It has been reported evidence of an association of hepatic
ﬁbrosis and angiogenesis by TLR-4 through MyD88 on liver
endothelial cells [39]. TLR-4 has been identiﬁed as one of
the seven genes associated with increased risk of developing
cirrhosis in patients infected with Hepatitis C virus (HCV)
[40, 41]. TLR-3 bounded to poly I:C induces activation of
NK cells [42] which can destroy HSCs, and produces IFN-
gammatoinduceapoptosisandinhibitproliferationofHSCs
leading to inhibition of liver ﬁbrosis [43, 44].
7. TLRs in LiverRegeneration
Liver regeneration is a complex process orchestrated by
several signaling pathways induced by cytokines, growth
factors,andhormones.Experimentalstudiessuggestthatloss
of liver tissue or cell damage is caused by innate immune
response to liver regeneration. The role of TLR-4 signaling
in liver regeneration has been widely investigated through
MyD88 [34] on alcohol injury and development of hepatic
steatosis [45, 46]. TLR-3 on bladder epithelial cells not
only plays an important role by protecting against viral
infection through secretion of IFN-gamma [47] but also
causesapoptosisofinfectedlivercellsandhasbeenassociated
with pathogenesis of biliary atresia [48]. It also inhibits
liver regeneration of damaged hepatocyte apoptosis and
interrupts the cell cycle (cyclin dependent (e.g., cyclin D1))6 Gastroenterology Research and Practice
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Figure 1: Toll-like receptors on secondary obstructive cholangiopathies.
throughactivationoftransducersandactivatorsoftranscrip-
tion signal-1 (STAT-1) [49].
8.TLRs inLiverDiseases
8.1. Secondary Obstructive Cholangiopathy. Human bile is
sterile under normal conditions. Acute cholangitis is a biliary
tract infection characterized by fever, right upper quadrant
abdominal pain, and jaundice [50] .I t se t i o l o g yi sd i v e r s e ,
including choledocholithiasis, biliary atresia, and complete
obstruction of the bile ducts after cholecystectomy. For the
cholangitis to develop bile stasis is required with increased
bladder pressure and presence of microorganisms in bile
ducts, being the most common pathogens Gram-negative
bacteria [51]. If not resolved soon, it can evolve to sepsis
and systemic inﬂammatory response syndrome leading to
high morbidity and mortality with inadequate hepatic and
systemic response in presence of LPS [52].
Biliary epithelial cells are immunologically potent. In
presence of bile duct inﬂammation these cells secrete cy-
tokines which express immunity receptors further recog-
nizing microbes through PRRs. TLRs are the better recog-
nizer of PAMPs. Upon exposure to LPS, immunity cells are
activated and they transduce intracellular adaptative signals
associated with TLRs, induce NF-κB expression, and secrete
proinﬂammatory cytokines.
It has been conﬁrmed by immunohistochemistry that
TLR-1/TLR-5 are distributed diﬀusely in intrahepatic biliary
tract on healthy human liver. Biliary epithelial cells possess
TLRs signaling systems which actively participate in cellular
immunity [20, 53]. Increased expression of TLR-4 in biliary
epithelium after experimental bile duct obstruction pro-
motes chronic inﬂammation and hepatic periportal ﬁbrosis
which depends on the increase of LPS binding proteins
[10]. TLR-4 role in acute cholangitis has not yet been fully
elucidated.
Upon epithelium exposure to pathogen particles, adap-
tive immunity induces resistance against microorganisms by
rearrangements of genes encoding T cellreceptors producing
high levels of diﬀerent receptors in response to attacks by
pathogens. It is well known that acquired resistance is notGastroenterology Research and Practice 7
transmitted vertically and reﬂects the individual experience
of each organism to previous infections. In contrast, innate
immune receptors recognize antigens by speciﬁc PRR recep-
tors which are vertically transmitted by germ cells where
antigen recognition induces an immediate inﬂammatory
response to control infection by opsonization, chemotaxis,
and activation of leukocytes. As mentioned previously,
TLRsinduceinﬂammatoryresponseagainstmicroorganisms
through activation of NF-κB as it induces transcription of
many genes including cytokines such as TNF, IFN, IL-2, IL-
8, and IL-12 and defensins within minutes after pathogens
injurycausinginﬂammationinordertodestroytheinfection
and generate immunological memory against [54].
Knowing the intricate inﬂammation mechanisms of
epithelium bile duct injury, it is essential to develop
alternative therapies aimed to prevent immune-mediated
destruction of biliary tract associated with cholangiopathy.
Four cholangiopathies characterized by secondary biliary
obstruction will be discussed brieﬂy, capable of producing
secondary biliary cirrhosis. Liver cirrhosis will also be
addressed, and ﬁnally some alternative management related
to TLRs.
8.2. Biliary Atresia. Biliary atresia is characterized by a pro-
gressive inﬂammatory sclerosing obstructive cholangiopathy
which appears within the ﬁrst afterbirth months. The precise
etiology and pathogenesis remains unknown; it could be
caused by viral infection with Reoviridae (reovirus type
3, type C rotavirus, adenovirus, Cytomegalovirus, Estein-
Barr, and others), even though biopsy results obtained
during Kasai procedure are contradictory [55]. Immuno-
histochemical analysis of early innate immune response
proteins with molecular markers for Mx is highly sensitive
to type I interferon, and they are also reported as positive
in hepatocytes and intrahepatic bile ducts in biliary atresia,
suggesting the presence of viral infections [56, 57]. It is
possible that biliary endothelial cells are targets of these
viruses producing atresia. Even when survival of patients
improves signiﬁcantly with Kasai procedure, more than half
of aﬀected children will develop cirrhosis and will require
liver transplantation [58].
A previous study published by Huang et al. found
signiﬁcantly increased expression of TLR-5 and MxA mRNA
in liver biopsy from early biliary atresia. These results imply
the participation of TLR-7 and type 1 interferon signaling
in the pathogenesis of biliary atresia, speciﬁcally on early
stages and its association with overproduction of IL-8 [59].
Despitetheabovementioned,muchremainstobeelucidated
regarding TLRs and biliary atresia.
8.3. Hepatolithiasis. It is considered a bile duct disease
histologically characterized by formation of gallstones and
chronic proliferative cholangitis. Reported incidence in
western countries is about 1%, although it is not rare
in Asia (including Japan). Its natural history can lead to
development of biliary cirrhosis, portal hypertension, and
liver failure, with risk of cholangiocarcinoma in approx-
imately 10% of patients. Bacterial infections of biliary
tract and presence of cholestasis have been implicated as
the main etiopathogenic factor of lithogenesis in patients
with calcium bilirubinate stones, and Escherichia coli (β-
glucuronidase) is the most frequently isolated bacteria in bile
ducts. On the other hand, DNA of Campylobacter species
has been reported by PCR in bile and bladder biopsies
from patients with hepatolithiasis [60]. It is speculated that
these bacteria in biliary epithelium inﬂuence the emergence
and development of cholangitis and lithogenesis, through
interaction of PAMPs and TLRs, although its mechanism
remains unclear.
8.4. Bile Duct Injury after Cholecystectomy. TLRs role in
patients with bile duct injury after cholecystectomy has not
been elucidated. Experimental studies on animals submitted
to bile duct ligation have been reported; however, human
reactions are not analogous to those on experimental mod-
els. Secondary obstructive congenital or acquired cholan-
giopathies generate signiﬁcant morbidity and mortality in
both children and adults because cholangiocytes proliferate
at the ﬁnal stage of the disease, resulting in bile duct
destruction, liver ﬁbrosis, following cirrhosis and ﬁnally
liver failure. We have to look into the behavior of TLRs in
serum and liver tissue biopsies from patients with biliary
atresia, hepatolithiasis, biliary injury previously undergone
cholecystectomy, and primary biliary cirrhosis in order to
describe the role of TLRs for planning alternative surgical or
biomolecular treatment strategies.
8.5. Cirrhosis. Patients with liver cirrhosis have chronic
endotoxemia, elevated serum TNF-α,I L - 1 β, and IL-6 due to
activation of Kupﬀer cells, and high baseline levels of LPS-
induced TLR-4 expression. However, regulation of TLR-4 is
altered in monocytes from cirrhotic patients which produce
frequent bacterial infections [61].
8.6. Primary Biliary Cirrhosis. Primary biliary cirrhosis
has an immune etiology and produces biochemical and
structural alterations of the liver acting as an obstructive
cholangiopathy. Patients with chronic liver diseases regard-
lessof etiology arelikely to develop liver ﬁbrosisthat canlead
to cirrhosis with consequent complications such as portal
hypertension and/or liver failure. All chronic liver diseases
including cholangiopathy generate a constant process of
ﬁbrosis where the innate immune system and activation of
monocytes and NK cells induce chronic inﬂammation [62].
Primary biliary cirrhosis is characterized by destruction of
intrahepatic bile ducts through autoimmune mechanisms
apparently caused in response to inﬂammatory cytokines.
There are also several reports suggesting that pathogenic
microorganisms are involved in the pathogenesis of the
disease [63]. TLRs and type I IFN play an important role
in innate and adaptive immune response, and as mentioned
before type I IFN has the ability to induce maturation
of DC during antigen presentation and direct cellular
diﬀerentiation by MHC and induces antibody production.
Type 1 IFN may be implicated in the pathogenesis of
autoimmunity in primary biliary cirrhosis and is induced by8 Gastroenterology Research and Practice
TLR-3,TLR-4,TLR-7,andTLR-9[64].Anincidenceincrease
of recurrent urinary tract infections in patients with primary
biliary cirrosis has been reported; furthermore, other studies
supporttheassociationbetweenurinaryorvaginalinfections
with endotoxemia in bile ducts due to proteins, nucleic acids,
orPAMPsthatinduceinﬂammation.Someauthorsspeculate
that these may be responsible for cholangitis that occurs in
primary biliary cirrhosis [65].
8.7. Management Alternatives for
Secondary Biliary Cholangiopathy
8.7.1. TLRs Blockade. Speciﬁc activation of TLR-2 in hep-
atitis C and homo- or heterodimerization with TLR-1
or TLR-6 has been shown; also, when these are blocked
a signiﬁcant decrease on production of proinﬂammatory
cytokines appears, suggesting that some proteins produced
by hepatitis C activate innate immune [12]. TLR-9-deﬁcient
mice manifest less liver injury in response to carbon
tetrachloride, bile duct ligation, acetaminophen, and steato-
hepatitis. Overexpression of TGF-β can be blocked by TLR-
9 antagonists [26]. TLR-2 deﬁciency appears to play a
protectiveroleininductionofnonalcoholicfattyliverdisease
andprobablymodifyTLR-4signaling[16].TLR-2andTLR-4
induceendotoxemiaclearanceinplasma[33].TLR-3inhibits
liverregenerationofdamagedhepatocyteapoptosisandseize
cellcyclethroughsignalingtranscriptionactivators-1(STAT-
1) [49]. Therefore, it is important to perform clinical trials
and experimental studies on protein-deﬁcient animals in
order to understand the biochemical and immunological
mechanisms that may be susceptible to modiﬁcation to
improve pathogenic response to microorganisms in sec-
ondary obstructive cholangiopathy, thus, preventing liver
ﬁbrosis, cirrhosis, and portal hypertension.
8.7.2. TLRs Stimulation. TLR-1, TLR-2, TLR-3, TLR-7, TLR-
8, TLR-9, and TLR-10 induce type 1 IFN production
during viral infections [19]. TLR-3 poly I:C-linked induces
activation of NK42 cells which destroy HSCs and IFN-
gamma production by inducing apoptosis and inhibition
of HSCs proliferation, leading to liver ﬁbrosis restrain [43,
44]. TLR-3 in biliary epithelial cells protects against viral
infections by secretion of IFN-gamma, inducing apopto-
sis of infected hepatocytes, as reported in biliary atresia.
Moreover, there are some antimicrobial peptides produced
by epithelial cells called human β-defensins induced by
inﬂammatory stimuli and produced speciﬁcally on infection
site. β-defensins interact on bacteria membrane through
exchange of hydrophobic amino acids. They are expressed
mainly on epithelial cells and have a broad activity spectrum
against Gram-positive and Gram-negative bacteria, fungi,
and certain viruses [66]. All of the above are strong research
possibilities; however, it would be worthwhile to develop
prospective clinical trials to be carried out in bile cultures
for searching Gram-positive and Gram-negative bacteria,
anaerobic bacteria, viruses, and fungi, as well as evaluating
TLRs and β-defensins behaviour in secondary obstructive
cholangiopathy in patients at hospital admission and at
hospital discharge considering as variable the administration
of antibiotic therapy. Agonists of TLR-7 and TLR9 are under
consideration in the management of hepatitis C [67]. The
better understanding of the role played by TLRs in secondary
obstructive cholangiopathy would oﬀer more and improved
therapeutic options aimed to prevent adverse outcomes for
these pathologies.
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